BIIB vs EBS · P/E 21, rev $9.89B vs rev $1.04B
Biogen Inc (BIIB) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. EBS currently screens at market cap $416.4M.
Not investment advice. Open the BIIB and EBS stock pages for the full models.
Not investment advice.